



Atty. Dkt. No. 023533-0144

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Thomas D. HORN

Title:

IMMUNOTHERAPY OF EPITHELIAL TUMORS USING INTRALESIONAL INJECTION OF ANTIGENS THAT

INDUCE A DELAYED TYPE HYPERSENSITIVITY

**REACTION** 

Appl. No.:

10/081,185

Filing Date:

02/25/2002

Examiner:

Unassigned

Art Unit:

1642

## **AMENDMENT TRANSMITTAL**

Commissioner for Patents Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

[X] Small Entity status under 37 C.F.R. § 1.9 and § 1.27 has been established by a Small Entity statement previously submitted.

[X] The fee required for additional claims is calculated below:

|                  | Claims<br>as<br>Amended                        |         | Previously<br>Paid For |        | Extra<br>Claims<br>Present |      | Rate       |   | Additional<br>Claims Fee |
|------------------|--|---------|------------------------|--------|----------------------------|------|------------|---|--------------------------|
| Total Claims:    | 47   | _       | 32                     | =      | 15                         | ×    | \$18.00    | = | \$270.00                 |
| Independents:    | 2  | -       | 3                      | =      | 0                          | ×    | \$84.00    |   | \$0.00                   |
| First presentati | on of any M                                    | ultiple | e Dependen             | t Clai | ms:                        | +    | \$280.00   | = | \$0.00                   |
|                  |  |         |                        |        | CL                         | AIMS | FEE TOTAL: | = | \$270.00                 |
|                  | CLAIMS AND EXTENSION FEE TOTAL:                |         |                        |        |                            |      |            |   | \$270.00                 |
| [ X ]            | Small Entity Fees Apply (subtract ½ of above): |         |                        |        |                            |      |            | ٠ | \$135.00                 |
|                  | TOTAL FEE:                                     |         |                        |        |                            |      |            |   | \$135.00                 |

[X] A check in the amount of \$135.00 is enclosed.

[X] The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741. If any extensions of time are needed for timely acceptance of papers submitted herewith, applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date //

**FOLEY & LARDNER** 

Customer Number: 22428

22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5483 Facsimile: (202) 672-5399 Jayme A. Huleatt
Attorney for Applicant

Registration No. 34,485

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

Thomas Dag HORN et al.

Title:

IMMUNOTHERAPY OF EPITHELIAL TUMORS USING INTRALESIONAL INJECTION OF ANTIGENS THAT

INDUCE A DELAYED TYPE HYPERSENSITIVITY

REACTION

Appl. No.:

10/081,185

Filing Date:

02/25/2002

Examiner:

Unassigned

Art Unit:

1642

## PRELIMINARY AMENDMENT

Commissioner for Patents Box PATENT APPLICATION Washington, D.C. 20231

Sir:

Prior to examination of the present Divisonal Application, Applicant respectfully requests that the application be amended as follows:

## In the Claims:

Kindly add the following claims:

(New) The pharmaceutical composition of claim 1, wherein said pharmaceutical 33. composition does not contain an immunogenic additive other than said antigens.

- (New) The pharmaceutical composition of claim 1, wherein said antigens are 34. equivalent in purity to an allergenic extract for intradermal testing.
- (New) The pharmaceutical composition of claim 1, wherein at least one of said 35. antigens is equivalent in purity to an allergenic extract for intradermal testing.

03/19/2003 HABDELR1 00000115 10081185